Skip to main content
Premium Trial:

Request an Annual Quote

Ciphergen Receives Noncompliance Letter from Nasdaq

NEW YORK (GenomeWeb News) - Ciphergen Biosystems said last week that it has received a letter from Nasdaq indicating that it is not in compliance the exchange’s listing requirements.
 
Specifically, Nasdaq warned Ciphergen that it is not compliant with Marketplace Rule 4310(c)(3), which requires it to have a minimum of $2.5 million in stockholders' equity; $35 million market value of listed securities; or $500,000 of net income from continuing operations for the most recently completed fiscal year or two of the three most recently completed fiscal years.
 
Ciphergen has 30 calendar days, or until Sept. 14, 2007, to regain compliance.
 
If the company doesn’t meet these requirements by that date, it faces delisting.

The Scan

Mosquitos Genetically Modified to Prevent Malaria Spread

A gene drive approach could be used to render mosquitos unable to spread malaria, researchers report in Science Advances.

Gut Microbiomes Allow Bears to Grow to Similar Sizes Despite Differing Diets

Researchers in Scientific Reports find that the makeup of brown bears' gut microbiomes allows them to reach similar sizes even when feasting on different foods.

Finding Safe Harbor in the Human Genome

In Genome Biology, researchers present a new approach to identify genomic safe harbors where transgenes can be expressed without affecting host cell function.

New Data Point to Nuanced Relationship Between Major Depression, Bipolar Disorder

Lund University researchers in JAMA Psychiatry uncover overlapping genetic liabilities for major depression and bipolar disorder.